Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.
Experts say this new migraine medication, the first in 50 years, shows great promise. Here’s what you need to know, including the cost implications
The new Bipartisan Budget Act of 2018, to be in effect on January 2019, institutes new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.
How skipping industry acronyms and jargon and using simple terminology will eliminate confusion and misinterpretation.
An ONC report finds that more patients are engaged with their health records. Here’s why.
The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.
To get a pulse on the U.S.
Douglas Long, vice president of industry relations at Durham, NC-based IQVIA, a newly named company after the merger of IMS Health and Quintiles, discussed pharmaceutical marketplace trends during the headline session at the Academy of Ma
The cost to treat cancer in the United States could reach $156 billion in 2020, according to the National Cancer Institute. And innovative medications have a significant impact on the cost of care.
Gene therapy, which got its start in the 1960s, is finally starting to take hold.